Should We Prescribe SGLT-2 Inhibitors for All Patients with Chronic Kidney Disease?

Sodium–glucose cotransporter-2 (SGLT-2) inhibitors inhibit progression of chronic kidney disease, but the benefits in patients with mild kidney disease are uncertain. To learn more, researchers conducted a meta-analysis of 10 randomized, placebo-controlled trials comprising 70,000 patients with FDA indications for SGLT-2 inhibitors (i.e., type 2 diabetes, heart failure, or chronic kidney disease) to examine renal outcomes stratified by baseline estimated glomerular filtration rate (eGFR) and albuminuria. The primary outcome was a composite of kidney failure, death due to kidney failure, and at least 50% reduction in eGFR.